1. Home
  2. DSGN vs FXNC Comparison

DSGN vs FXNC Comparison

Compare DSGN & FXNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • FXNC
  • Stock Information
  • Founded
  • DSGN 2017
  • FXNC 1907
  • Country
  • DSGN United States
  • FXNC United States
  • Employees
  • DSGN N/A
  • FXNC N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • FXNC Major Banks
  • Sector
  • DSGN Health Care
  • FXNC Finance
  • Exchange
  • DSGN Nasdaq
  • FXNC Nasdaq
  • Market Cap
  • DSGN 208.9M
  • FXNC 200.1M
  • IPO Year
  • DSGN 2021
  • FXNC N/A
  • Fundamental
  • Price
  • DSGN $6.03
  • FXNC $23.30
  • Analyst Decision
  • DSGN
  • FXNC
  • Analyst Count
  • DSGN 0
  • FXNC 0
  • Target Price
  • DSGN N/A
  • FXNC N/A
  • AVG Volume (30 Days)
  • DSGN 171.5K
  • FXNC 11.9K
  • Earning Date
  • DSGN 11-06-2025
  • FXNC 10-31-2025
  • Dividend Yield
  • DSGN N/A
  • FXNC 2.66%
  • EPS Growth
  • DSGN N/A
  • FXNC N/A
  • EPS
  • DSGN N/A
  • FXNC 0.96
  • Revenue
  • DSGN N/A
  • FXNC $71,824,000.00
  • Revenue This Year
  • DSGN N/A
  • FXNC $57.18
  • Revenue Next Year
  • DSGN N/A
  • FXNC $5.15
  • P/E Ratio
  • DSGN N/A
  • FXNC $24.33
  • Revenue Growth
  • DSGN N/A
  • FXNC 46.30
  • 52 Week Low
  • DSGN $2.60
  • FXNC $16.92
  • 52 Week High
  • DSGN $7.77
  • FXNC $26.97
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 58.00
  • FXNC 60.56
  • Support Level
  • DSGN $5.65
  • FXNC $23.15
  • Resistance Level
  • DSGN $6.65
  • FXNC $23.62
  • Average True Range (ATR)
  • DSGN 0.51
  • FXNC 0.28
  • MACD
  • DSGN -0.00
  • FXNC -0.07
  • Stochastic Oscillator
  • DSGN 64.27
  • FXNC 35.00

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About FXNC First National Corporation

First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. Key revenue is generated from Community Banking.

Share on Social Networks: